Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Dimer-specific immunoprecipitation of active caspase-2 identifies TRAF proteins as novel activators.

Robeson AC, Lindblom KR, Wojton J, Kornbluth S, Matsuura K.

EMBO J. 2018 Jun 6. pii: e97072. doi: 10.15252/embj.201797072. [Epub ahead of print]

2.

Humanized chondroitinase ABC sensitizes glioblastoma cells to temozolomide.

Jaime-Ramirez AC, Dmitrieva N, Yoo JY, Banasavadi-Siddegowda Y, Zhang J, Relation T, Bolyard C, Wojton J, Kaur B.

J Gene Med. 2017 Mar;19(3). doi: 10.1002/jgm.2942.

3.

BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection-Implications for Oncolytic Viral Therapy.

Bolyard C, Meisen WH, Banasavadi-Siddegowda Y, Hardcastle J, Yoo JY, Wohleb ES, Wojton J, Yu JG, Dubin S, Khosla M, Xu B, Smith J, Alvarez-Breckenridge C, Pow-Anpongkul P, Pichiorri F, Zhang J, Old M, Zhu D, Van Meir EG, Godbout JP, Caligiuri MA, Yu J, Kaur B.

Clin Cancer Res. 2017 Apr 1;23(7):1809-1819. doi: 10.1158/1078-0432.CCR-16-1818. Epub 2016 Nov 9.

4.

Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy.

Yoo JY, Jaime-Ramirez AC, Bolyard C, Dai H, Nallanagulagari T, Wojton J, Hurwitz BS, Relation T, Lee TJ, Lotze MT, Yu JG, Zhang J, Croce CM, Yu J, Caligiuri MA, Old M, Kaur B.

Clin Cancer Res. 2016 Nov 1;22(21):5265-5276. Epub 2016 Jul 7. Erratum in: Clin Cancer Res. 2017 Mar 1;23 (5):1359-1360.

5.

How to train glioma cells to die: molecular challenges in cell death.

Wojton J, Meisen WH, Kaur B.

J Neurooncol. 2016 Feb;126(3):377-84. doi: 10.1007/s11060-015-1980-1. Epub 2015 Nov 5.

6.

Metabolic control of Ca2+/calmodulin-dependent protein kinase II (CaMKII)-mediated caspase-2 suppression by the B55β/protein phosphatase 2A (PP2A).

Huang B, Yang CS, Wojton J, Huang NJ, Chen C, Soderblom EJ, Zhang L, Kornbluth S.

J Biol Chem. 2014 Dec 26;289(52):35882-90. doi: 10.1074/jbc.M114.585844. Epub 2014 Nov 4.

7.

SapC-DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma.

Wojton J, Meisen WH, Jacob NK, Thorne AH, Hardcastle J, Denton N, Chu Z, Dmitrieva N, Marsh R, Van Meir EG, Kwon CH, Chakravarti A, Qi X, Kaur B.

Oncotarget. 2014 Oct 30;5(20):9703-9.

8.

Aurora-A inhibition offers a novel therapy effective against intracranial glioblastoma.

Van Brocklyn JR, Wojton J, Meisen WH, Kellough DA, Ecsedy JA, Kaur B, Lehman NL.

Cancer Res. 2014 Oct 1;74(19):5364-70. doi: 10.1158/0008-5472.CAN-14-0386. Epub 2014 Aug 8.

9.

How efficient are autophagy inhibitors as treatment for glioblastoma?

Wojton J, Elder J, Kaur B.

CNS Oncol. 2014 Jan;3(1):5-7. doi: 10.2217/cns.13.52. No abstract available.

10.

Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.

Yan F, Alinari L, Lustberg ME, Martin LK, Cordero-Nieves HM, Banasavadi-Siddegowda Y, Virk S, Barnholtz-Sloan J, Bell EH, Wojton J, Jacob NK, Chakravarti A, Nowicki MO, Wu X, Lapalombella R, Datta J, Yu B, Gordon K, Haseley A, Patton JT, Smith PL, Ryu J, Zhang X, Mo X, Marcucci G, Nuovo G, Kwon CH, Byrd JC, Chiocca EA, Li C, Sif S, Jacob S, Lawler S, Kaur B, Baiocchi RA.

Cancer Res. 2014 Mar 15;74(6):1752-65. doi: 10.1158/0008-5472.CAN-13-0884. Epub 2014 Jan 22.

11.

Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma.

Wojton J, Chu Z, Mathsyaraja H, Meisen WH, Denton N, Kwon CH, Chow LM, Palascak M, Franco R, Bourdeau T, Thornton S, Ostrowski MC, Kaur B, Qi X.

Mol Ther. 2013 Aug;21(8):1517-25. doi: 10.1038/mt.2013.114. Epub 2013 Jun 4.

12.

NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors.

Alvarez-Breckenridge CA, Yu J, Price R, Wojton J, Pradarelli J, Mao H, Wei M, Wang Y, He S, Hardcastle J, Fernandez SA, Kaur B, Lawler SE, Vivier E, Mandelboim O, Moretta A, Caligiuri MA, Chiocca EA.

Nat Med. 2012 Dec;18(12):1827-34. doi: 10.1038/nm.3013. Epub 2012 Nov 25.

13.

Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV.

Yoo JY, Pradarelli J, Haseley A, Wojton J, Kaka A, Bratasz A, Alvarez-Breckenridge CA, Yu JG, Powell K, Mazar AP, Teknos TN, Chiocca EA, Glorioso JC, Old M, Kaur B.

Clin Cancer Res. 2012 Sep 15;18(18):4931-41. Epub 2012 Jul 2.

14.

Extracellular matrix protein CCN1 limits oncolytic efficacy in glioma.

Haseley A, Boone S, Wojton J, Yu L, Yoo JY, Yu J, Kurozumi K, Glorioso JC, Caligiuri MA, Kaur B.

Cancer Res. 2012 Mar 15;72(6):1353-62. doi: 10.1158/0008-5472.CAN-11-2526. Epub 2012 Jan 26.

15.

Impact of tumor microenvironment on oncolytic viral therapy.

Wojton J, Kaur B.

Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):127-34. doi: 10.1016/j.cytogfr.2010.02.014. Review.

Supplemental Content

Loading ...
Support Center